

JUL 25 2001

K011869

510(k) SUMMARY

**XENF-DP Rhino-Laryngofiberscope,  
its accessories and ancillary equipment**

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR, Section 807.92.

**A. Submitter's Name, Address, Phone and Fax Number**

**1. Manufacturer of the subject device**

Name & Address of Manufacturer;	Olympus Optical Co., Ltd. 2-3-1 Shinjuku Monolis Nishi-shinjuku Shinjuku-ku, Tokyo, 163-0914 Japan
Registration No :	810047
Address, Phone and Fax Number of R&D Department Endoscope Division	2951 Ishikawa-cho Hachioji-shi, Tokyo 192-8507 Japan TEL 81-426-42-5177 FAX 81-426-46-5613

**2 Name of Contact Person**

Name :	Ms.Laura Storms-Tyler Director, Regulatory Affairs Olympus America Inc.
Address, Phone and Fax	Olympus America Inc. Two Corporate Center Drive Melville, NY 11747-3157 TEL (631) 844-5688 FAX (631) 844-5416

**B. Device Name, Common Name**

1. Device Name :	XENF-DP Rhino-Laryngofiberscope, its accessories and ancillary equipment
2. Common/Usual Name :	Fiber Scope for Rhino-Laryngofiberscope
3. Classification Name :	21CFR 876.1500 21CFR 868.5530 21CFR 874.4760

### C. Predicate Devices :

<b>Model</b>	<b>Device Description &amp; 510(k)#/ Date of Cleared</b>	<b>Manufacturer</b>
Pentax Naso-Pharyngo-Laryngoscope FNL-15P2/15RP2	#K921707 07/01/1992	Pentax Precision Instrument Corp
LF-TP/DP Tracheal Intubation Fiberscopes	#K981543 08/06/1998	Olympus Optical Co.,
LF-DP Gastrointestinal and Sigmoid Fiberscope	#K002231 1/30/2001	Olympus Optical Co.,

### D. Summary Description of the Device

#### 1. Summary

This subject device “XENF-DP Rhino-Laryngofiberscope” is used for observation within nasal and nasopharyngeal lumen. This endoscope enables use of 2 types of light sources, a detachable single use battery light source powered and a light cable light source.

#### 2. Design

“XENF-DP Rhino-Laryngofiberscope” has been designed, manufactured and tested in compliance with voluntary safety standards. It meets the requirements of IEC 60601-1 and IEC60601-2-18.

#### 3. Materials

There are no new patient-contacting materials. All of patient contact materials are cleared by previous 510(k) submissions.

### E. Intended Use of the device

This instrument has been designed to be used with an Olympus Light Source or an Olympus Miniature Light Source, documentation equipment, display monitor, and other ancillary equipment for endoscopic diagnosis within the upper airway which includes the nasal cavity, nasopharynx, oropharynx, hypopharynx and larynx.

### F. Technological Characteristics

This endoscope does not have special technological characteristics, when compared to the predicate device.

### G. Reason for not requiring clinical data

When compared to the predicate devices, “XENF-DP Rhino-Laryngofiberscope” does not incorporate any significant change for safety and efficacy to the predicate device. Observation within nasal and nasopharyngeal lumen has been done widely, and established its safety and effectiveness, therefore clinical data is not necessary for its evaluation of its safety and efficacy.



**JUL 25 2001**

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Olympus Optical Co., Ltd.  
c/o Laura Storms-Tyler  
Director, Regulatory Affairs  
Olympus America, Inc.  
Two Corporate Center Drive  
Melville, NY 11747-3157

Re: K011869  
Trade Name: Olympus XENF-DP Rhino-Laryngofiberscope  
Regulation Number: 21 CFR 874.4760  
Regulatory Class: Class II  
Product Code: EOB  
Dated: June 11, 2001  
Received: June 14, 2001

Dear Ms. Tyler:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-6413. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



A. Ralph Rosenthal, M.D.  
Director  
Division of Ophthalmic and Ear,  
Nose and Throat Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

